Abstract: The present disclosure relates to a modified polypeptide having xylanase activity and use thereof.

Abstract: Disclosed is a modified polypeptide having mannanase activity and a use thereof.

Abstract: Disclosed is a modified polypeptide having mannanase activity and a use thereof.

Abstract: A clock generation circuit includes a reference voltage generator configured to generate a first current having a current value inversely proportional to a reference voltage and a temperature, a bias circuit configured to generate a bias current, a second current having a current value proportional to the temperature, and a third current based on the reference voltage, a voltage generator configured to generate a supply voltage based on the first current, the bias current, and the second current, and an oscillation circuit configured to generate a clock signal having a constant frequency based on the supply voltage and the third current, wherein the supply voltage is generated to have a slope based on a ratio of the first current to the second current.

Abstract: The present disclosure relates to a fructose-C4-epimerase and a method of preparing tagatose using the same.

Abstract: The present disclosure relates to a method for preparing a transglucosylated steviol glycoside using a crude enzyme liquid of a Lactobacillus mali strain.

Abstract: The present invention provides a thermoplastic resin composition which includes: a first copolymer including a core including a conjugated diene-based polymer and a shell including an aromatic vinyl-based monomer unit and a vinyl cyan-based monomer unit; and a second copolymer including an aromatic vinyl-based monomer unit and a vinyl cyan-based monomer unit, wherein the first copolymer has a degree of grafting of 32 to 50%, the second copolymer has a weight-average molecular weight of 85,000 to 115,000 g/mol, and the thermoplastic resin composition includes the first copolymer at 30 wt % or less and an oligomer residue at 1.1 wt % or less. Specifically, the thermoplastic resin composition can shorten an injection molding time.

Abstract: The present disclosure relates to a modified polypeptide having xylanase activity and the use thereof.

Abstract: A composition for preventing and/or treating cytokine release syndrome and a method of prevention and/or treatment of cytokine release syndrome are disclosed. The composition includes an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. The cytokine release syndrome may be caused by virulent infection. The administration of the compound reduces the pre-inflammatory cytokine levels in the subject.

Abstract: The present disclosure relates to a modified polypeptide having xylanase activity and the use thereof.

Abstract: Provided are a fructose-4-epimerase variant having tagatose conversion activity, and a method of preparing tagatose using the same.

Abstract: The present disclosure is a pharmaceutical composition for the prevention or treatment of sepsis containing a thiamine derivative or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition of the present disclosure can be used for the prevention, alleviation, or treatment of sepsis by containing fursultiamine or allithiamine to inhibit the expressions of CD40, CD86, and TNF?.

Abstract: A composition for preventing and/or treating cytokine release syndrome and a method of prevention and/or treatment of cytokine release syndrome are disclosed. The composition includes an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. The cytokine release syndrome may be caused by virulent infection. The administration of the compound reduces the pre-inflammatory cytokine levels in the subject.

Abstract: A method of determining a precise orbit of a satellite through estimation of a parallactic refraction scale factor is proposed, the method includes inputting an initial estimate including initial orbit information of a satellite with respect to an observation epoch and the parallactic refraction scale factor; performing orbit propagation using a high-precision orbit propagator by applying a dynamics model; performing observer-centered satellite optical observation modeling including the parallactic refraction scale factor; calculating an observation residual between actual optical observation data and observation data calculated via the observation modeling reflecting the parallactic refraction; and precisely determining the orbit of the satellite by estimating the parallactic refraction scale factor and a satellite state vector using a batch least square estimation algorithm.

Abstract: A method for re-entry prediction of an uncontrolled artificial space object includes: calculating an average semi-major axis and an argument of latitude by inputting two-line elements or osculating elements of an artificial space object at two different time points; calculating an average semi-major axis, argument of latitude, and atmospheric drag at a second time point; estimating an optimum drag scale factor while changing the drag scale factor; predicting the time and place of re-entry of an artificial space object into the atmosphere by applying the estimated drag scale factor. Here, orbit prediction is performed by using a Cowell's high-precision orbital propagator using numerical integration from the second time point to a re-entry time point.

Abstract: The present invention relates to a pharmaceutical composition for preventing, treating, or ameliorating graft versus host disease (GVHD), comprising thiamine derivatives, in which the active ingredient of the pharmaceutical composition is fursultiamine, which can alleviate weight loss found in patients with GVHD, reduce the infiltration of liver and colon inflammatory cells, and effectively inhibit the production of allogeneic CD4+ IFN?+ T cells, and thus can be effectively used for the prevention, treatment, or amelioration of GVHD.

Abstract: Provided are a tagatose-bisphosphate aldolase variant having tagatose conversion activity, and a method of preparing tagatose using the same.

Abstract: Provided are a novel fructose-C4-epimerase and a method of producing tagatose using the same.

Abstract: Disclosed is a thermoplastic resin composition, a method of preparing the same, and a molded article including the same. Also disclosed is a thermoplastic resin composition including a base resin including a vinyl cyanide compound-conjugated diene rubber-aromatic vinyl compound graft copolymer, an alkyl acrylate rubber-vinyl cyanide compound-aromatic vinyl compound graft copolymer, and an aromatic vinyl compound-vinyl cyanide compound copolymer and a polysiloxane in a predetermined composition ratio, wherein the alkyl acrylate rubber-vinyl cyanide compound-aromatic vinyl compound graft copolymer has a grafting degree of 42% or more and is included in an amount of 0.1 to 10% by weight based on 100% by weight in total of the base resin.

Abstract: The present disclosure relates to a composition for tagatose production and a method for preparing tagatose using the same.